Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Liting Guo
Crizotinib as a Personalized Alternative for Targeted Anaplastic Lymphoma Kinase Rearrangement in Previously Treated Patients With non-Small-Cell Lung Cancer
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Related publications
Alectinib in Untreated Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Annals of Translational Medicine
Medicine
P1.13-02 eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Diagnostic Assays for Identification of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Cancer
Cancer Research
Oncology
Clinical Challenges in Targeting Anaplastic Lymphoma Kinase in Advanced Non-Small Cell Lung Cancer
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer
Lung Cancer: Targets and Therapy
Oncology
Expanding Anaplastic Lymphoma Kinase Therapeutic Indication to Early Stage Non-Small Cell Lung Cancer
Translational Lung Cancer Research
Oncology
Pcn140 - Cost-Effectiveness Analysis of Alectinib vs Crizotinib in First Line Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
P3.01-30 Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Are Anaplastic Lymphoma Kinase Gene Rearrangements in Non-Small Cell Lung Cancer Prognostic, Predictive, or Both?
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
